Corporate Profile ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules.  ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate.  ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize ridaforolimus, ARIAD's lead cancer product candidate, which is in Phase 3 clinical development.  ARIAD's second oncology product candidate, oral AP24534, is a novel multi-targeted kinase inhibitor in Phase 1 clinical development in hematological cancers.  ARIAD has an exclusive license to pioneering technology and patents related to certain NF-kB treatment methods, and the discovery and development of drugs to regulate NF-kB cell-signaling activity, which may be useful in treating certain diseases.

Contact Information Address ARIAD Pharmaceuticals, Inc. 26 Landsdowne St. Cambridge, MA 02139-4234  Phone (617) 494-0400 Fax (617) 494-8144 IR Contact Maria Cantor Vice President, Corporate Communications and Investor Relations Phone 617-621-2345 E-mail investor@ariad.com Home page www.ariad.com

Corporate Governance Harvey J. Berger, M.D. Chairman and Chief Executive Officer David Berstein, Esq. Senior Vice President and Chief Intellectual Property Officer Daniel M. Bollag, Ph.D. Senior Vice President of Regulatory Affairs and Quality Joseph Bratica Vice President, Finance and Controller Maria E. Cantor Vice President, Corporate Communications and Investor Relations Timothy P. Clackson, Ph.D. Senior Vice President and Chief Scientific Officer David C. Dalgarno, Ph.D. Vice President, Research Technologies Virginia R. Dean Vice President, Human Resources Pierre F. Dodion, M.D. Senior Vice President and Chief Medical Officer Edward M. Fitzgerald Senior Vice President, Chief Financial Officer and Treasurer Frank G. Haluska, M.D., Ph.D. Vice President, Clinical Affairs Shirish Hirani, Ph.D. Vice President, Program and Alliance Management Raymond T. Keane, Esq. Senior Vice President, General Counsel, Secretary and Chief Compliance Officer John D. Iuliucci, Ph.D. Senior Vice President, Development John W. Loewy, Ph.D. Vice President, Biostatistics and Outcomes Research Ross D. Pettit Vice President, Clinical Operations Victor M. Rivera, Ph.D. Vice President, Preclinical and Translational Research Matthew E. Ros Senior Vice President, Commercial Operations Kelly M. Schmitz Vice President, Information Technology and Operations William C. Shakespeare, Ph.D. Vice President, Drug Discovery Andreas Woppmann, Ph.D. Vice President, Manufacturing Operations Directors Harvey J. Berger, M.D. Chairman and Chief Executive Officer, ARIAD Pharmaceuticals, Inc. Jay R. LaMarche Former Executive Vice President, Chief Financial Officer and Treasurer, ARIAD Pharmaceuticals, Inc. Athanase Lavidas, Ph.D Chairman and Chief Executive Officer, Lavipharm Group Massimo Radaelli, Ph.D President and Chief Executive Officer of Dompé International SA A. Collier Smyth, M.D Former Senior Vice President of Medical Strategy – Oncology at Bristol-Myers Squibb Company Wayne Wilson Independent Business Advisor

Shareholder Information Exchange NASDAQ Global Market (.O) Stock Quote (ARIA) 2.16  As of 20-Nov-2009 4:00 PM Minimum 20 minutes delayed NASDAQ Biotech 801.05 (-0.39%) Listed Security ARIA Common Stock Transfer Agent Computershare Trust Company, N.A. PO Box 43023 Providence, RI 02940-3023  Phone (877) 282-1169 Corporate Counsel Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. One Financial Ctr. Boston, MA 02111-2620  Independent Accountants Deloitte & Touche LLP 200 Berkeley Street Boston, MA 02116-5022